Past Recipients
2023 - Kelly Trinh, MD
“What is the added value of concurrent diagnostic CT for PSMA PET/CT imaging assessment of prostate cancer?”
2022 - Wanqi Chen
2021 - Mohammad Naghavi-Behzad, MD, MPH
“Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT”
2020 - Abhishek Jha, MBBS
2019 - Jeremie Calais, MD
2018 - Sungwook Jung, PhD
2017 - Raiyan Tripti Zaman, PhD
2016 - Yong-il Kim
“Prognostic Value of Pre-treatment Ga-68-RGD PET-CT in Predicting Disease Free Survival in Patients with Breast Cancer: A Comparison Study with Dynamic Contrast Enhanced MRI.”
2015 - Chrystalla Loutsios
"SPECT/CT to quantify eosinophil migration into the lungs"
2014 - Jean-François Montégiani
Personalized 177 Lu-octreotate PPRT: cycle-to-cycle renal radiation dose prediction using quantitative SPECT/CT dosimetry
2013 - Matthias Eiber, MD, PhD
“Initial experience in restaging of patients with recurrent prostate cancer: Comparison of 11C-Choline-PET/MR and 11C-Choline-PET/CT”
2012 - Hai Jeon Yoon, MD
"Predicting histologic biomarker expression in breast cancer with 68Ga-RGD PET/CT versus diffusion-weighted and dynamic contrast-enhanced MRI"
2011 - Masahiro Yanagawa, MD, PhD
"Comparison of PET Response Criteria in Solid Tumors (PERCIST) and Response Evaluation Criteria in Solid Tumors (RECIST) in neoadjuvant chemotherapy for esophageal cancer"
2010 - Andrew Quon, MD
“Correlation between MRI and NaF PET/CT in patients with patellofemoral knee pain”
2009 - Patrick Veit-Haibach, MD
“Impact of F18-DOPA PET/CT on therapeutic management in patients neuroendocrine tumors”
2008 - Donna J. Cross, PhD
“Olfactory tract dysintegrity and cortical metabolic change in aging and MCI.”
2007 - Jan Soyka, MD
"Staging Pathways in Recurrent Colorectal Carcinoma. Is Contrast-enhanced 18-FDG-PET-CT the Diagnostic Tool of Choice?"